-
1
-
-
27144449009
-
Monoclonal antibody therapy of cancer
-
Adams G.P., and Weiner L.M. Monoclonal antibody therapy of cancer. Nat. Biotechnol. 23 (2005) 1147
-
(2005)
Nat. Biotechnol.
, vol.23
, pp. 1147
-
-
Adams, G.P.1
Weiner, L.M.2
-
2
-
-
0345596439
-
Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver
-
Alexander Jr. H.R., Bartlett D.L., Libutti S.K., Fraker D.L., Moser T., and Rosenberg S.A. Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver. J. Clin. Oncol. 16 (1998) 1479
-
(1998)
J. Clin. Oncol.
, vol.16
, pp. 1479
-
-
Alexander Jr., H.R.1
Bartlett, D.L.2
Libutti, S.K.3
Fraker, D.L.4
Moser, T.5
Rosenberg, S.A.6
-
3
-
-
0032535052
-
Emerging applications of recombinant human granulocyte-macrophage colony-stimulating factor
-
Armitage J.O. Emerging applications of recombinant human granulocyte-macrophage colony-stimulating factor. Blood 92 (1998) 4491
-
(1998)
Blood
, vol.92
, pp. 4491
-
-
Armitage, J.O.1
-
4
-
-
0030889207
-
The IFN gamma receptor: a paradigm for cytokine receptor signaling
-
Bach E.A., Aguet M., and Schreiber R.D. The IFN gamma receptor: a paradigm for cytokine receptor signaling. Annu. Rev. Immunol. 15 (1997) 563
-
(1997)
Annu. Rev. Immunol.
, vol.15
, pp. 563
-
-
Bach, E.A.1
Aguet, M.2
Schreiber, R.D.3
-
5
-
-
33646407812
-
Targeted delivery of tumor necrosis factor-alpha to tumor vessels induces a therapeutic T cell-mediated immune response that protects the host against syngeneic tumors of different histologic origin
-
Balza E., Mortara L., Sassi F., Monteghirfo S., Carnemolla B., Castellani P., Neri D., Accolla R.S., Zardi L., and Borsi L. Targeted delivery of tumor necrosis factor-alpha to tumor vessels induces a therapeutic T cell-mediated immune response that protects the host against syngeneic tumors of different histologic origin. Clin. Cancer Res. 12 (2006) 2575
-
(2006)
Clin. Cancer Res.
, vol.12
, pp. 2575
-
-
Balza, E.1
Mortara, L.2
Sassi, F.3
Monteghirfo, S.4
Carnemolla, B.5
Castellani, P.6
Neri, D.7
Accolla, R.S.8
Zardi, L.9
Borsi, L.10
-
6
-
-
0029890827
-
T cell-mediated eradication of murine metastatic melanoma induced by targeted interleukin 2 therapy
-
Becker J.C., Pancook J.D., Gillies S.D., Furukawa K., and Reisfeld R.A. T cell-mediated eradication of murine metastatic melanoma induced by targeted interleukin 2 therapy. J. Exp. Med. 183 (1996) 2361
-
(1996)
J. Exp. Med.
, vol.183
, pp. 2361
-
-
Becker, J.C.1
Pancook, J.D.2
Gillies, S.D.3
Furukawa, K.4
Reisfeld, R.A.5
-
7
-
-
26444432323
-
Radioimmunotherapy of solid tumors by targeting extra domain B fibronectin: identification of the best-suited radioimmunoconjugate
-
Berndorff D., Borkowski S., Sieger S., Rother A., Friebe M., Viti F., Hilger C.S., Cyr J.E., and Dinkelborg L.M. Radioimmunotherapy of solid tumors by targeting extra domain B fibronectin: identification of the best-suited radioimmunoconjugate. Clin. Cancer Res. 11 (2005) 7053s
-
(2005)
Clin. Cancer Res.
, vol.11
-
-
Berndorff, D.1
Borkowski, S.2
Sieger, S.3
Rother, A.4
Friebe, M.5
Viti, F.6
Hilger, C.S.7
Cyr, J.E.8
Dinkelborg, L.M.9
-
8
-
-
0032827243
-
Selective targeting and photocoagulation of ocular angiogenesis mediated by a phage-derived human antibody fragment
-
Birchler M., Viti F., Zardi L., Spiess B., and Neri D. Selective targeting and photocoagulation of ocular angiogenesis mediated by a phage-derived human antibody fragment. Nat. Biotechnol. 17 (1999) 984
-
(1999)
Nat. Biotechnol.
, vol.17
, pp. 984
-
-
Birchler, M.1
Viti, F.2
Zardi, L.3
Spiess, B.4
Neri, D.5
-
9
-
-
0037827261
-
Expression of the extra domain B of fibronectin, a marker of angiogenesis, in head and neck tumors
-
Birchler M.T., Milisavlijevic D., Pfaltz M., Neri D., Odermatt B., Schmid S., and Stoeckli S.J. Expression of the extra domain B of fibronectin, a marker of angiogenesis, in head and neck tumors. Laryngoscope 113 (2003) 1231
-
(2003)
Laryngoscope
, vol.113
, pp. 1231
-
-
Birchler, M.T.1
Milisavlijevic, D.2
Pfaltz, M.3
Neri, D.4
Odermatt, B.5
Schmid, S.6
Stoeckli, S.J.7
-
10
-
-
34047221616
-
Immunoscintigraphy of patients with head and neck carcinomas, with an anti-angiogenetic antibody fragment
-
Birchler M.T., Thuerl C., Schmid D., Neri D., Waibel R., Schubiger A., Stoeckli S.J., Schmid S., and Goerres G.W. Immunoscintigraphy of patients with head and neck carcinomas, with an anti-angiogenetic antibody fragment. Otolaryngol. Head Neck Surg. 136 (2007) 543
-
(2007)
Otolaryngol. Head Neck Surg.
, vol.136
, pp. 543
-
-
Birchler, M.T.1
Thuerl, C.2
Schmid, D.3
Neri, D.4
Waibel, R.5
Schubiger, A.6
Stoeckli, S.J.7
Schmid, S.8
Goerres, G.W.9
-
12
-
-
0036837633
-
Selective targeting of tumoral vasculature: comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin
-
Borsi L., Balza E., Bestagno M., Castellani P., Carnemolla B., Biro A., Leprini A., Sepulveda J., Burrone O., Neri D., and Zardi L. Selective targeting of tumoral vasculature: comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin. Int. J. Cancer 102 (2002) 75
-
(2002)
Int. J. Cancer
, vol.102
, pp. 75
-
-
Borsi, L.1
Balza, E.2
Bestagno, M.3
Castellani, P.4
Carnemolla, B.5
Biro, A.6
Leprini, A.7
Sepulveda, J.8
Burrone, O.9
Neri, D.10
Zardi, L.11
-
13
-
-
10744221996
-
Selective targeted delivery of TNFalpha to tumor blood vessels
-
Borsi L., Balza E., Carnemolla B., Sassi F., Castellani P., Berndt A., Kosmehl H., Biro A., Siri A., Orecchia P., Grassi J., Neri D., and Zardi L. Selective targeted delivery of TNFalpha to tumor blood vessels. Blood 102 (2003) 4384
-
(2003)
Blood
, vol.102
, pp. 4384
-
-
Borsi, L.1
Balza, E.2
Carnemolla, B.3
Sassi, F.4
Castellani, P.5
Berndt, A.6
Kosmehl, H.7
Biro, A.8
Siri, A.9
Orecchia, P.10
Grassi, J.11
Neri, D.12
Zardi, L.13
-
14
-
-
0034716486
-
Therapeutic monoclonal antibodies
-
Breedveld F.C. Therapeutic monoclonal antibodies. Lancet 355 (2000) 735
-
(2000)
Lancet
, vol.355
, pp. 735
-
-
Breedveld, F.C.1
-
15
-
-
0027239503
-
Antitumor and antimetastatic activity of interleukin 12 against murine tumors
-
Brunda M.J., Luistro L., Warrier R.R., Wright R.B., Hubbard B.R., Murphy M., Wolf S.F., and Gately M.K. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J. Exp. Med. 178 (1993) 1223
-
(1993)
J. Exp. Med.
, vol.178
, pp. 1223
-
-
Brunda, M.J.1
Luistro, L.2
Warrier, R.R.3
Wright, R.B.4
Hubbard, B.R.5
Murphy, M.6
Wolf, S.F.7
Gately, M.K.8
-
16
-
-
0024594936
-
A tumor-associated fibronectin isoform generated by alternative splicing of messenger RNA precursors
-
Carnemolla B., Balza E., Siri A., Zardi L., Nicotra M.R., Bigotti A., and Natali P.G. A tumor-associated fibronectin isoform generated by alternative splicing of messenger RNA precursors. J. Cell Biol. 108 (1989) 1139
-
(1989)
J. Cell Biol.
, vol.108
, pp. 1139
-
-
Carnemolla, B.1
Balza, E.2
Siri, A.3
Zardi, L.4
Nicotra, M.R.5
Bigotti, A.6
Natali, P.G.7
-
17
-
-
0036493867
-
Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix
-
Carnemolla B., Borsi L., Balza E., Castellani P., Meazza R., Berndt A., Ferrini S., Kosmehl H., Neri D., and Zardi L. Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix. Blood 99 (2002) 1659
-
(2002)
Blood
, vol.99
, pp. 1659
-
-
Carnemolla, B.1
Borsi, L.2
Balza, E.3
Castellani, P.4
Meazza, R.5
Berndt, A.6
Ferrini, S.7
Kosmehl, H.8
Neri, D.9
Zardi, L.10
-
18
-
-
0029802551
-
Phage antibodies with pan-species recognition of the oncofoetal angiogenesis marker fibronectin ED-B domain
-
Carnemolla B., Neri D., Castellani P., Leprini A., Neri G., Pini A., Winter G., and Zardi L. Phage antibodies with pan-species recognition of the oncofoetal angiogenesis marker fibronectin ED-B domain. Int. J. Cancer 68 (1996) 397
-
(1996)
Int. J. Cancer
, vol.68
, pp. 397
-
-
Carnemolla, B.1
Neri, D.2
Castellani, P.3
Leprini, A.4
Neri, G.5
Pini, A.6
Winter, G.7
Zardi, L.8
-
19
-
-
45749104147
-
Granulocyte-macrophage colony-stimulating factor potentiates rituximab in patients with relapsed follicular lymphoma: results of a phase II study
-
Cartron G., Zhao-Yang L., Baudard M., Kanouni T., Rouille V., Quittet P., Klein B., and Rossi J.F. Granulocyte-macrophage colony-stimulating factor potentiates rituximab in patients with relapsed follicular lymphoma: results of a phase II study. J. Clin. Oncol. 26 (2008) 2725
-
(2008)
J. Clin. Oncol.
, vol.26
, pp. 2725
-
-
Cartron, G.1
Zhao-Yang, L.2
Baudard, M.3
Kanouni, T.4
Rouille, V.5
Quittet, P.6
Klein, B.7
Rossi, J.F.8
-
20
-
-
0036841992
-
Differentiation between high- and low-grade astrocytoma using a human recombinant antibody to the extra domain-B of fibronectin
-
Castellani P., Borsi L., Carnemolla B., Biro A., Dorcaratto A., Viale G.L., Neri D., and Zardi L. Differentiation between high- and low-grade astrocytoma using a human recombinant antibody to the extra domain-B of fibronectin. Am. J. Pathol. 161 (2002) 1695
-
(2002)
Am. J. Pathol.
, vol.161
, pp. 1695
-
-
Castellani, P.1
Borsi, L.2
Carnemolla, B.3
Biro, A.4
Dorcaratto, A.5
Viale, G.L.6
Neri, D.7
Zardi, L.8
-
21
-
-
0028116528
-
The fibronectin isoform containing the ED-B oncofetal domain: a marker of angiogenesis
-
Castellani P., Viale G., Dorcaratto A., Nicolo G., Kaczmarek J., Querze G., and Zardi L. The fibronectin isoform containing the ED-B oncofetal domain: a marker of angiogenesis. Int. J. Cancer 59 (1994) 612
-
(1994)
Int. J. Cancer
, vol.59
, pp. 612
-
-
Castellani, P.1
Viale, G.2
Dorcaratto, A.3
Nicolo, G.4
Kaczmarek, J.5
Querze, G.6
Zardi, L.7
-
22
-
-
0028824039
-
IL-12 deaths: explanation and a puzzle
-
Cohen J. IL-12 deaths: explanation and a puzzle. Science 270 (1995) 908
-
(1995)
Science
, vol.270
, pp. 908
-
-
Cohen, J.1
-
23
-
-
0036005890
-
Interleukin-12 in anti-tumor immunity and immunotherapy
-
Colombo M.P., and Trinchieri G. Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev. 13 (2002) 155
-
(2002)
Cytokine Growth Factor Rev.
, vol.13
, pp. 155
-
-
Colombo, M.P.1
Trinchieri, G.2
-
24
-
-
0036369434
-
In vivo tumor delivery of a recombinant single chain Fv::tumor necrosis factor-alpha fusion [correction of factor: a fusion] protein
-
Cooke S.P., Pedley R.B., Boden R., Begent R.H., and Chester K.A. In vivo tumor delivery of a recombinant single chain Fv::tumor necrosis factor-alpha fusion [correction of factor: a fusion] protein. Bioconjug. Chem. 13 (2002) 7
-
(2002)
Bioconjug. Chem.
, vol.13
, pp. 7
-
-
Cooke, S.P.1
Pedley, R.B.2
Boden, R.3
Begent, R.H.4
Chester, K.A.5
-
25
-
-
33644789357
-
Chemo-immunotherapy of metastatic colorectal carcinoma with gemcitabine plus FOLFOX 4 followed by subcutaneous granulocyte macrophage colony-stimulating factor and interleukin-2 induces strong immunologic and antitumor activity in metastatic colon cancer patients
-
Correale P., Cusi M.G., Tsang K.Y., Del Vecchio M.T., Marsili S., Placa M.L., Intrivici C., Aquino A., Micheli L., Nencini C., Ferrari F., Giorgi G., Bonmassar E., and Francini G. Chemo-immunotherapy of metastatic colorectal carcinoma with gemcitabine plus FOLFOX 4 followed by subcutaneous granulocyte macrophage colony-stimulating factor and interleukin-2 induces strong immunologic and antitumor activity in metastatic colon cancer patients. J. Clin. Oncol. 23 (2005) 8950
-
(2005)
J. Clin. Oncol.
, vol.23
, pp. 8950
-
-
Correale, P.1
Cusi, M.G.2
Tsang, K.Y.3
Del Vecchio, M.T.4
Marsili, S.5
Placa, M.L.6
Intrivici, C.7
Aquino, A.8
Micheli, L.9
Nencini, C.10
Ferrari, F.11
Giorgi, G.12
Bonmassar, E.13
Francini, G.14
-
26
-
-
23844494526
-
Immunotherapy of renal cell carcinoma with granulocyte macrophage colony stimulating factor and very low dose interleukin-2
-
Correale P., Marsili S., Sabatino M., Montagnani F., Giorgi G., and Francini G. Immunotherapy of renal cell carcinoma with granulocyte macrophage colony stimulating factor and very low dose interleukin-2. Oncol. Rep. 13 (2005) 751
-
(2005)
Oncol. Rep.
, vol.13
, pp. 751
-
-
Correale, P.1
Marsili, S.2
Sabatino, M.3
Montagnani, F.4
Giorgi, G.5
Francini, G.6
-
27
-
-
1642434101
-
Coupling tumor necrosis factor-alpha with alphaV integrin ligands improves its antineoplastic activity
-
Curnis F., Gasparri A., Sacchi A., Longhi R., and Corti A., Coupling tumor necrosis factor-alpha with alphaV integrin ligands improves its antineoplastic activity. Cancer Res. 64 (2004) 565
-
(2004)
Cancer Res.
, vol.64
, pp. 565
-
-
Curnis, F.1
Gasparri, A.2
Sacchi, A.3
Longhi, R.4
Corti, A.5
-
28
-
-
0033764170
-
Enhancement of tumor necrosis factor alpha antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13)
-
Curnis F., Sacchi A., Borgna L., Magni F., Gasparri A., and Corti A. Enhancement of tumor necrosis factor alpha antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13). Nat. Biotechnol. 18 (2000) 1185
-
(2000)
Nat. Biotechnol.
, vol.18
, pp. 1185
-
-
Curnis, F.1
Sacchi, A.2
Borgna, L.3
Magni, F.4
Gasparri, A.5
Corti, A.6
-
31
-
-
0037471398
-
Protein vaccination with the HER2/neu extracellular domain plus anti-HER2/neu antibody-cytokine fusion proteins induces a protective anti-HER2/neu immune response in mice
-
Dela Cruz J.S., Lau S.Y., Ramirez E.M., De Giovanni C., Forni G., Morrison S.L., and Penichet M.L. Protein vaccination with the HER2/neu extracellular domain plus anti-HER2/neu antibody-cytokine fusion proteins induces a protective anti-HER2/neu immune response in mice. Vaccine 21 (2003) 1317
-
(2003)
Vaccine
, vol.21
, pp. 1317
-
-
Dela Cruz, J.S.1
Lau, S.Y.2
Ramirez, E.M.3
De Giovanni, C.4
Forni, G.5
Morrison, S.L.6
Penichet, M.L.7
-
32
-
-
0034327810
-
Recombinant anti-human HER2/neu IgG3-(GM-CSF) fusion protein retains antigen specificity and cytokine function and demonstrates antitumor activity
-
Dela Cruz J.S., Trinh K.R., Morrison S.L., and Penichet M.L. Recombinant anti-human HER2/neu IgG3-(GM-CSF) fusion protein retains antigen specificity and cytokine function and demonstrates antitumor activity. J. Immunol. 165 (2000) 5112
-
(2000)
J. Immunol.
, vol.165
, pp. 5112
-
-
Dela Cruz, J.S.1
Trinh, K.R.2
Morrison, S.L.3
Penichet, M.L.4
-
33
-
-
42649114787
-
Local therapy of cancer with free IL-2
-
Den Otter W., Jacobs J.J., Battermann J.J., Hordijk G.J., Krastev Z., Moiseeva E.V., Stewart R.J., Ziekman P.G., and Koten J.W. Local therapy of cancer with free IL-2. Cancer Immunol. Immunother. 57 (2008) 931
-
(2008)
Cancer Immunol. Immunother.
, vol.57
, pp. 931
-
-
Den Otter, W.1
Jacobs, J.J.2
Battermann, J.J.3
Hordijk, G.J.4
Krastev, Z.5
Moiseeva, E.V.6
Stewart, R.J.7
Ziekman, P.G.8
Koten, J.W.9
-
34
-
-
0019955969
-
Positive self regulation of cytotoxicity in human natural killer cells by production of interferon upon exposure to influenza and herpes viruses
-
Djeu J.Y., Stocks N., Zoon K., Stanton G.J., Timonen T., and Herberman R.B. Positive self regulation of cytotoxicity in human natural killer cells by production of interferon upon exposure to influenza and herpes viruses. J. Exp. Med. 156 (1982) 1222
-
(1982)
J. Exp. Med.
, vol.156
, pp. 1222
-
-
Djeu, J.Y.1
Stocks, N.2
Zoon, K.3
Stanton, G.J.4
Timonen, T.5
Herberman, R.B.6
-
35
-
-
22044456976
-
Engineered vascular-targeting antibody-interferon-gamma fusion protein for cancer therapy
-
Ebbinghaus C., Ronca R., Kaspar M., Grabulovski D., Berndt A., Kosmehl H., Zardi L., and Neri D. Engineered vascular-targeting antibody-interferon-gamma fusion protein for cancer therapy. Int. J. Cancer 116 (2005) 304
-
(2005)
Int. J. Cancer
, vol.116
, pp. 304
-
-
Ebbinghaus, C.1
Ronca, R.2
Kaspar, M.3
Grabulovski, D.4
Berndt, A.5
Kosmehl, H.6
Zardi, L.7
Neri, D.8
-
36
-
-
0029738520
-
Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial
-
Eggermont A.M., Schraffordt Koops H., Lienard D., Kroon B.B., van Geel A.N., Hoekstra H.J., and Lejeune F.J. Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial. J. Clin. Oncol. 14 (1996) 2653
-
(1996)
J. Clin. Oncol.
, vol.14
, pp. 2653
-
-
Eggermont, A.M.1
Schraffordt Koops, H.2
Lienard, D.3
Kroon, B.B.4
van Geel, A.N.5
Hoekstra, H.J.6
Lejeune, F.J.7
-
37
-
-
58349112507
-
TNF-alpha and the IFN-gamma-inducible protein 10 (IP-10/CXCL-10) delivered by parvoviral vectors act in synergy to induce antitumor effects in mouse glioblastoma
-
Enderlin M., Kleinmann E.V., Struyf S., Buracchi C., Vecchi A., Kinscherf R., Kiessling F., Paschek S., Sozzani S., Rommelaere J., Cornelis J.J., Van Damme J., and Dinsart C. TNF-alpha and the IFN-gamma-inducible protein 10 (IP-10/CXCL-10) delivered by parvoviral vectors act in synergy to induce antitumor effects in mouse glioblastoma. Cancer Gene Ther. 16 (2009) 149
-
(2009)
Cancer Gene Ther.
, vol.16
, pp. 149
-
-
Enderlin, M.1
Kleinmann, E.V.2
Struyf, S.3
Buracchi, C.4
Vecchi, A.5
Kinscherf, R.6
Kiessling, F.7
Paschek, S.8
Sozzani, S.9
Rommelaere, J.10
Cornelis, J.J.11
Van Damme, J.12
Dinsart, C.13
-
38
-
-
0027411525
-
The molecular cell biology of interferon-gamma and its receptor
-
Farrar M.A., and Schreiber R.D. The molecular cell biology of interferon-gamma and its receptor. Annu. Rev. Immunol. 11 (1993) 571
-
(1993)
Annu. Rev. Immunol.
, vol.11
, pp. 571
-
-
Farrar, M.A.1
Schreiber, R.D.2
-
39
-
-
0025877853
-
Genetic construction and characterization of a fusion protein consisting of a chimeric F(ab') with specificity for carcinomas and human IL-2
-
Fell H.P., Gayle M.A., Grosmaire L., and Ledbetter J.A. Genetic construction and characterization of a fusion protein consisting of a chimeric F(ab') with specificity for carcinomas and human IL-2. J. Immunol. 146 (1991) 2446
-
(1991)
J. Immunol.
, vol.146
, pp. 2446
-
-
Fell, H.P.1
Gayle, M.A.2
Grosmaire, L.3
Ledbetter, J.A.4
-
40
-
-
0023700112
-
Granulocyte-macrophage colony-stimulating factor activates macrophages derived from bone marrow cultures to synthesis of MHC class II molecules and to augmented antigen presentation function
-
Fischer H.G., Frosch S., Reske K., and Reske-Kunz A.B. Granulocyte-macrophage colony-stimulating factor activates macrophages derived from bone marrow cultures to synthesis of MHC class II molecules and to augmented antigen presentation function. J. Immunol. 141 (1988) 3882
-
(1988)
J. Immunol.
, vol.141
, pp. 3882
-
-
Fischer, H.G.1
Frosch, S.2
Reske, K.3
Reske-Kunz, A.B.4
-
41
-
-
0027467414
-
Tumor-necrosis factor can enhance radio-antibody uptake in human colon carcinoma xenografts by increasing vascular permeability
-
Folli S., Pelegrin A., Chalandon Y., Yao X., Buchegger F., Lienard D., Lejeune F., and Mach J.P. Tumor-necrosis factor can enhance radio-antibody uptake in human colon carcinoma xenografts by increasing vascular permeability. Int. J. Cancer 53 (1993) 829
-
(1993)
Int. J. Cancer
, vol.53
, pp. 829
-
-
Folli, S.1
Pelegrin, A.2
Chalandon, Y.3
Yao, X.4
Buchegger, F.5
Lienard, D.6
Lejeune, F.7
Mach, J.P.8
-
42
-
-
0036790091
-
Mice lacking the EDB segment of fibronectin develop normally but exhibit reduced cell growth and fibronectin matrix assembly in vitro
-
Fukuda T., Yoshida N., Kataoka Y., Manabe R., Mizuno-Horikawa Y., Sato M., Kuriyama K., Yasui N., and Sekiguchi K. Mice lacking the EDB segment of fibronectin develop normally but exhibit reduced cell growth and fibronectin matrix assembly in vitro. Cancer Res. 62 (2002) 5603
-
(2002)
Cancer Res.
, vol.62
, pp. 5603
-
-
Fukuda, T.1
Yoshida, N.2
Kataoka, Y.3
Manabe, R.4
Mizuno-Horikawa, Y.5
Sato, M.6
Kuriyama, K.7
Yasui, N.8
Sekiguchi, K.9
-
43
-
-
33748866249
-
An engineered antibody-interleukin-12 fusion protein with enhanced tumor vascular targeting properties
-
Gafner V., Trachsel E., and Neri D. An engineered antibody-interleukin-12 fusion protein with enhanced tumor vascular targeting properties. Int. J. Cancer 119 (2006) 2205
-
(2006)
Int. J. Cancer
, vol.119
, pp. 2205
-
-
Gafner, V.1
Trachsel, E.2
Neri, D.3
-
44
-
-
0025604195
-
Retroviral vector-mediated gamma-interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity
-
Gansbacher B., Bannerji R., Daniels B., Zier K., Cronin K., and Gilboa E. Retroviral vector-mediated gamma-interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity. Cancer Res. 50 (1990) 7820
-
(1990)
Cancer Res.
, vol.50
, pp. 7820
-
-
Gansbacher, B.1
Bannerji, R.2
Daniels, B.3
Zier, K.4
Cronin, K.5
Gilboa, E.6
-
45
-
-
0036042603
-
Bi-functional cytokine fusion proteins for gene therapy and antibody-targeted treatment of cancer
-
Gillies S.D., Lan Y., Brunkhorst B., Wong W.K., Li Y., and Lo K.M. Bi-functional cytokine fusion proteins for gene therapy and antibody-targeted treatment of cancer. Cancer Immunol. Immunother. 51 (2002) 449
-
(2002)
Cancer Immunol. Immunother.
, vol.51
, pp. 449
-
-
Gillies, S.D.1
Lan, Y.2
Brunkhorst, B.3
Wong, W.K.4
Li, Y.5
Lo, K.M.6
-
46
-
-
0027598183
-
Biological activity and in vivo clearance of antitumor antibody/cytokine fusion proteins
-
Gillies S.D., Young D., Lo K.M., and Roberts S. Biological activity and in vivo clearance of antitumor antibody/cytokine fusion proteins. Bioconjug. Chem. 4 (1993) 230
-
(1993)
Bioconjug. Chem.
, vol.4
, pp. 230
-
-
Gillies, S.D.1
Young, D.2
Lo, K.M.3
Roberts, S.4
-
47
-
-
0023932445
-
Clearance and distribution of recombinant murine gamma-interferon in mice
-
Gonias S.L., Pizzo S.V., and Hoffman M. Clearance and distribution of recombinant murine gamma-interferon in mice. Cancer Res. 48 (1988) 2021
-
(1988)
Cancer Res.
, vol.48
, pp. 2021
-
-
Gonias, S.L.1
Pizzo, S.V.2
Hoffman, M.3
-
49
-
-
32844472410
-
Technology insight: Utility of TNF-alpha-based isolated limb perfusion to avoid amputation of irresectable tumors of the extremities
-
Grunhagen D.J., de Wilt J.H., ten Hagen T.L., and Eggermont A.M. Technology insight: Utility of TNF-alpha-based isolated limb perfusion to avoid amputation of irresectable tumors of the extremities. Nat. Clin. Pract. Oncol. 3 (2006) 94
-
(2006)
Nat. Clin. Pract. Oncol.
, vol.3
, pp. 94
-
-
Grunhagen, D.J.1
de Wilt, J.H.2
ten Hagen, T.L.3
Eggermont, A.M.4
-
50
-
-
0037731516
-
Synergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleukin 12 and to tumor necrosis factor alpha
-
Halin C., Gafner V., Villani M.E., Borsi L., Berndt A., Kosmehl H., Zardi L., and Neri D. Synergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleukin 12 and to tumor necrosis factor alpha. Cancer Res. 63 (2003) 3202
-
(2003)
Cancer Res.
, vol.63
, pp. 3202
-
-
Halin, C.1
Gafner, V.2
Villani, M.E.3
Borsi, L.4
Berndt, A.5
Kosmehl, H.6
Zardi, L.7
Neri, D.8
-
51
-
-
0036194917
-
Enhancement of the antitumor activity of interleukin-12 by targeted delivery to neovasculature
-
Halin C., Rondini S., Nilsson F., Berndt A., Kosmehl H., Zardi L., and Neri D. Enhancement of the antitumor activity of interleukin-12 by targeted delivery to neovasculature. Nat. Biotechnol. 20 (2002) 264
-
(2002)
Nat. Biotechnol.
, vol.20
, pp. 264
-
-
Halin, C.1
Rondini, S.2
Nilsson, F.3
Berndt, A.4
Kosmehl, H.5
Zardi, L.6
Neri, D.7
-
52
-
-
0030267660
-
In vivo properties of an IgG3-IL-2 fusion protein. A general strategy for immune potentiation
-
Harvill E.T., Fleming J.M., and Morrison S.L. In vivo properties of an IgG3-IL-2 fusion protein. A general strategy for immune potentiation. J. Immunol. 157 (1996) 3165
-
(1996)
J. Immunol.
, vol.157
, pp. 3165
-
-
Harvill, E.T.1
Fleming, J.M.2
Morrison, S.L.3
-
53
-
-
0029119763
-
Extracellular matrix proteins in colorectal carcinomas. Expression of tenascin and fibronectin isoforms
-
Hauptmann S., Zardi L., Siri A., Carnemolla B., Borsi L., Castellucci M., Klosterhalfen B., Hartung P., Weis J., Stocker G., et al. Extracellular matrix proteins in colorectal carcinomas. Expression of tenascin and fibronectin isoforms. Lab. Invest. 73 (1995) 172
-
(1995)
Lab. Invest.
, vol.73
, pp. 172
-
-
Hauptmann, S.1
Zardi, L.2
Siri, A.3
Carnemolla, B.4
Borsi, L.5
Castellucci, M.6
Klosterhalfen, B.7
Hartung, P.8
Weis, J.9
Stocker, G.10
-
54
-
-
2442710337
-
Engineering a thermostable human prolyl endopeptidase for antibody-directed enzyme prodrug therapy
-
Heinis C., Alessi P., and Neri D. Engineering a thermostable human prolyl endopeptidase for antibody-directed enzyme prodrug therapy. Biochemistry 43 (2004) 6293
-
(2004)
Biochemistry
, vol.43
, pp. 6293
-
-
Heinis, C.1
Alessi, P.2
Neri, D.3
-
55
-
-
0032946705
-
Prolonged neoadjuvant chemotherapy with GM-CSF in locally advanced breast cancer
-
Honkoop A.H., Luykx-de Bakker S.A., Hoekman K., Meyer S., Meyer O.W., van Groeningen C.J., van Diest P.J., Boven E., van der Wall E., Giaccone G., Wagstaff J., and Pinedo H.M. Prolonged neoadjuvant chemotherapy with GM-CSF in locally advanced breast cancer. Oncologist 4 (1999) 106
-
(1999)
Oncologist
, vol.4
, pp. 106
-
-
Honkoop, A.H.1
Luykx-de Bakker, S.A.2
Hoekman, K.3
Meyer, S.4
Meyer, O.W.5
van Groeningen, C.J.6
van Diest, P.J.7
Boven, E.8
van der Wall, E.9
Giaccone, G.10
Wagstaff, J.11
Pinedo, H.M.12
-
56
-
-
0024539057
-
Structure of tumour necrosis factor
-
Jones E.Y., Stuart D.I., and Walker N.P. Structure of tumour necrosis factor. Nature 338 (1989) 225
-
(1989)
Nature
, vol.338
, pp. 225
-
-
Jones, E.Y.1
Stuart, D.I.2
Walker, N.P.3
-
57
-
-
0028131531
-
Distribution of oncofetal fibronectin isoforms in normal, hyperplastic and neoplastic human breast tissues
-
Kaczmarek J., Castellani P., Nicolo G., Spina B., Allemanni G., and Zardi L. Distribution of oncofetal fibronectin isoforms in normal, hyperplastic and neoplastic human breast tissues. Int. J. Cancer 59 (1994) 11
-
(1994)
Int. J. Cancer
, vol.59
, pp. 11
-
-
Kaczmarek, J.1
Castellani, P.2
Nicolo, G.3
Spina, B.4
Allemanni, G.5
Zardi, L.6
-
58
-
-
34250315638
-
The antibody-mediated targeted delivery of interleukin-15 and GM-CSF to the tumor neovasculature inhibits tumor growth and metastasis
-
Kaspar M., Trachsel E., and Neri D. The antibody-mediated targeted delivery of interleukin-15 and GM-CSF to the tumor neovasculature inhibits tumor growth and metastasis. Cancer Res. 67 (2007) 4940
-
(2007)
Cancer Res.
, vol.67
, pp. 4940
-
-
Kaspar, M.1
Trachsel, E.2
Neri, D.3
-
59
-
-
33644518982
-
Fibronectin as target for tumor therapy
-
Kaspar M., Zardi L., and Neri D. Fibronectin as target for tumor therapy. Int. J. Cancer 118 (2006) 1331
-
(2006)
Int. J. Cancer
, vol.118
, pp. 1331
-
-
Kaspar, M.1
Zardi, L.2
Neri, D.3
-
60
-
-
3242664404
-
mRNA expression and protein distribution of the unspliced tenascin-C isoform in prostatic adenocarcinoma
-
Katenkamp K., Berndt A., Hindermann W., Wunderlich H., Haas K.M., Borsi L., Zardi L., and Kosmehl H. mRNA expression and protein distribution of the unspliced tenascin-C isoform in prostatic adenocarcinoma. J. Pathol. 203 (2004) 771
-
(2004)
J. Pathol.
, vol.203
, pp. 771
-
-
Katenkamp, K.1
Berndt, A.2
Hindermann, W.3
Wunderlich, H.4
Haas, K.M.5
Borsi, L.6
Zardi, L.7
Kosmehl, H.8
-
61
-
-
0027407459
-
Relationship between tissue factor expression and deposition of fibrin, platelets, and leukocytes on cultured endothelial cells under venous blood flow conditions
-
Kirchhofer D., Sakariassen K.S., Clozel M., Tschopp T.B., Hadvary P., Nemerson Y., and Baumgartner H.R. Relationship between tissue factor expression and deposition of fibrin, platelets, and leukocytes on cultured endothelial cells under venous blood flow conditions. Blood 81 (1993) 2050
-
(1993)
Blood
, vol.81
, pp. 2050
-
-
Kirchhofer, D.1
Sakariassen, K.S.2
Clozel, M.3
Tschopp, T.B.4
Hadvary, P.5
Nemerson, Y.6
Baumgartner, H.R.7
-
62
-
-
0029758308
-
Reduction of interstitial fluid pressure after TNF-alpha treatment of three human melanoma xenografts
-
Kristensen C.A., Nozue M., Boucher Y., and Jain R.K. Reduction of interstitial fluid pressure after TNF-alpha treatment of three human melanoma xenografts. Br. J. Cancer 74 (1996) 533
-
(1996)
Br. J. Cancer
, vol.74
, pp. 533
-
-
Kristensen, C.A.1
Nozue, M.2
Boucher, Y.3
Jain, R.K.4
-
63
-
-
0021969122
-
Pharmacokinetics, single-dose tolerance, and biological activity of recombinant gamma-interferon in cancer patients
-
Kurzrock R., Rosenblum M.G., Sherwin S.A., Rios A., Talpaz M., Quesada J.R., and Gutterman J.U. Pharmacokinetics, single-dose tolerance, and biological activity of recombinant gamma-interferon in cancer patients. Cancer Res. 45 (1985) 2866
-
(1985)
Cancer Res.
, vol.45
, pp. 2866
-
-
Kurzrock, R.1
Rosenblum, M.G.2
Sherwin, S.A.3
Rios, A.4
Talpaz, M.5
Quesada, J.R.6
Gutterman, J.U.7
-
65
-
-
0026531756
-
High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma
-
Lienard D., Ewalenko P., Delmotte J.J., Renard N., and Lejeune F.J. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J. Clin. Oncol. 10 (1992) 52
-
(1992)
J. Clin. Oncol.
, vol.10
, pp. 52
-
-
Lienard, D.1
Ewalenko, P.2
Delmotte, J.J.3
Renard, N.4
Lejeune, F.J.5
-
66
-
-
0033843152
-
Targeted cytokines for cancer immunotherapy
-
Lode H.N., and Reisfeld R.A. Targeted cytokines for cancer immunotherapy. Immunol. Res. 21 (2000) 279
-
(2000)
Immunol. Res.
, vol.21
, pp. 279
-
-
Lode, H.N.1
Reisfeld, R.A.2
-
67
-
-
0032031429
-
Natural killer cell-mediated eradication of neuroblastoma metastases to bone marrow by targeted interleukin-2 therapy
-
Lode H.N., Xiang R., Dreier T., Varki N.M., Gillies S.D., and Reisfeld R.A. Natural killer cell-mediated eradication of neuroblastoma metastases to bone marrow by targeted interleukin-2 therapy. Blood 91 (1998) 1706
-
(1998)
Blood
, vol.91
, pp. 1706
-
-
Lode, H.N.1
Xiang, R.2
Dreier, T.3
Varki, N.M.4
Gillies, S.D.5
Reisfeld, R.A.6
-
68
-
-
0034069669
-
What to do with targeted IL-2
-
Lode H.N., Xiang R., Perri P., Pertl U., Lode A., Gillies S.D., and Reisfeld R.A. What to do with targeted IL-2. Drugs Today (Barc) 36 (2000) 321
-
(2000)
Drugs Today (Barc)
, vol.36
, pp. 321
-
-
Lode, H.N.1
Xiang, R.2
Perri, P.3
Pertl, U.4
Lode, A.5
Gillies, S.D.6
Reisfeld, R.A.7
-
69
-
-
0024384319
-
IL-2 and IFN-gamma are two necessary lymphokines in the development of cytolytic T cells
-
Maraskovsky E., Chen W.F., and Shortman K. IL-2 and IFN-gamma are two necessary lymphokines in the development of cytolytic T cells. J. Immunol. 143 (1989) 1210
-
(1989)
J. Immunol.
, vol.143
, pp. 1210
-
-
Maraskovsky, E.1
Chen, W.F.2
Shortman, K.3
-
70
-
-
0036649819
-
Cytotoxic targeting of F9 teratocarcinoma tumours with anti-ED-B fibronectin scFv antibody modified liposomes
-
Marty C., Odermatt B., Schott H., Neri D., Ballmer-Hofer K., Klemenz R., and Schwendener R.A. Cytotoxic targeting of F9 teratocarcinoma tumours with anti-ED-B fibronectin scFv antibody modified liposomes. Br. J. Cancer 87 (2002) 106
-
(2002)
Br. J. Cancer
, vol.87
, pp. 106
-
-
Marty, C.1
Odermatt, B.2
Schott, H.3
Neri, D.4
Ballmer-Hofer, K.5
Klemenz, R.6
Schwendener, R.A.7
-
71
-
-
0026748230
-
Polyethylene-glycol-modified interleukin-2 is superior to interleukin-2 in locoregional immunotherapy of established guinea-pig tumors
-
Mattijssen V., Balemans L.T., Steerenberg P.A., and De Mulder P.H. Polyethylene-glycol-modified interleukin-2 is superior to interleukin-2 in locoregional immunotherapy of established guinea-pig tumors. Int. J. Cancer 51 (1992) 812
-
(1992)
Int. J. Cancer
, vol.51
, pp. 812
-
-
Mattijssen, V.1
Balemans, L.T.2
Steerenberg, P.A.3
De Mulder, P.H.4
-
72
-
-
0032530237
-
Targeting of interleukin 2 to human ovarian carcinoma by fusion with a single-chain Fv of antifolate receptor antibody
-
Melani C., Figini M., Nicosia D., Luison E., Ramakrishna V., Casorati G., Parmiani G., Eshhar Z., Canevari S., and Colombo M.P. Targeting of interleukin 2 to human ovarian carcinoma by fusion with a single-chain Fv of antifolate receptor antibody. Cancer Res. 58 (1998) 4146
-
(1998)
Cancer Res.
, vol.58
, pp. 4146
-
-
Melani, C.1
Figini, M.2
Nicosia, D.3
Luison, E.4
Ramakrishna, V.5
Casorati, G.6
Parmiani, G.7
Eshhar, Z.8
Canevari, S.9
Colombo, M.P.10
-
73
-
-
0036891467
-
An antibody-calmodulin fusion protein reveals a functional dependence between macromolecular isoelectric point and tumor targeting performance
-
Melkko S., Halin C., Borsi L., Zardi L., and Neri D. An antibody-calmodulin fusion protein reveals a functional dependence between macromolecular isoelectric point and tumor targeting performance. Int. J. Radiat. Oncol. Biol. Phys. 54 (2002) 1485
-
(2002)
Int. J. Radiat. Oncol. Biol. Phys.
, vol.54
, pp. 1485
-
-
Melkko, S.1
Halin, C.2
Borsi, L.3
Zardi, L.4
Neri, D.5
-
74
-
-
21244499009
-
ED-B fibronectin as a target for antibody-based cancer treatments
-
Menrad A., and Menssen H.D. ED-B fibronectin as a target for antibody-based cancer treatments. Expert Opin. Ther. Targets 9 (2005) 491
-
(2005)
Expert Opin. Ther. Targets
, vol.9
, pp. 491
-
-
Menrad, A.1
Menssen, H.D.2
-
75
-
-
0033983271
-
Source of oncofetal ED-B-containing fibronectin: implications of production by both tumor and endothelial cells
-
Midulla M., Verma R., Pignatelli M., Ritter M.A., Courtenay-Luck N.S., and George A.J. Source of oncofetal ED-B-containing fibronectin: implications of production by both tumor and endothelial cells. Cancer Res. 60 (2000) 164
-
(2000)
Cancer Res.
, vol.60
, pp. 164
-
-
Midulla, M.1
Verma, R.2
Pignatelli, M.3
Ritter, M.A.4
Courtenay-Luck, N.S.5
George, A.J.6
-
76
-
-
0023244861
-
Granulocyte-macrophage colony-stimulating factor augments the primary antibody response by enhancing the function of antigen-presenting cells
-
Morrissey P.J., Bressler L., Park L.S., Alpert A., and Gillis S. Granulocyte-macrophage colony-stimulating factor augments the primary antibody response by enhancing the function of antigen-presenting cells. J. Immunol. 139 (1987) 1113
-
(1987)
J. Immunol.
, vol.139
, pp. 1113
-
-
Morrissey, P.J.1
Bressler, L.2
Park, L.S.3
Alpert, A.4
Gillis, S.5
-
77
-
-
0028829105
-
Studies evaluating the antitumor activity and toxicity of interleukin-15, a new T cell growth factor: comparison with interleukin-2
-
Munger W., DeJoy S.Q., Jeyaseelan Sr. R., Torley L.W., Grabstein K.H., Eisenmann J., Paxton R., Cox T., Wick M.M., and Kerwar S.S. Studies evaluating the antitumor activity and toxicity of interleukin-15, a new T cell growth factor: comparison with interleukin-2. Cell Immunol. 165 (1995) 289
-
(1995)
Cell Immunol.
, vol.165
, pp. 289
-
-
Munger, W.1
DeJoy, S.Q.2
Jeyaseelan Sr., R.3
Torley, L.W.4
Grabstein, K.H.5
Eisenmann, J.6
Paxton, R.7
Cox, T.8
Wick, M.M.9
Kerwar, S.S.10
-
78
-
-
0026034432
-
Role of nitric oxide synthesis in macrophage antimicrobial activity
-
Nathan C.F., and Hibbs Jr. J.B. Role of nitric oxide synthesis in macrophage antimicrobial activity. Curr. Opin. Immunol. 3 (1991) 65
-
(1991)
Curr. Opin. Immunol.
, vol.3
, pp. 65
-
-
Nathan, C.F.1
Hibbs Jr., J.B.2
-
79
-
-
0030700632
-
Targeting by affinity-matured recombinant antibody fragments of an angiogenesis associated fibronectin isoform
-
Neri D., Carnemolla B., Nissim A., Leprini A., Querze G., Balza E., Pini A., Tarli L., Halin C., Neri P., Zardi L., and Winter G. Targeting by affinity-matured recombinant antibody fragments of an angiogenesis associated fibronectin isoform. Nat. Biotechnol. 15 (1997) 1271
-
(1997)
Nat. Biotechnol.
, vol.15
, pp. 1271
-
-
Neri, D.1
Carnemolla, B.2
Nissim, A.3
Leprini, A.4
Querze, G.5
Balza, E.6
Pini, A.7
Tarli, L.8
Halin, C.9
Neri, P.10
Zardi, L.11
Winter, G.12
-
80
-
-
0036074754
-
Quantitation of the tumor-targeting properties of antibody fragments conjugated to cell-permeating HIV-1 TAT peptides
-
Niesner U., Halin C., Lozzi L., Gunthert M., Neri P., Wunderli-Allenspach H., Zardi L., and Neri D. Quantitation of the tumor-targeting properties of antibody fragments conjugated to cell-permeating HIV-1 TAT peptides. Bioconjug. Chem. 13 (2002) 729
-
(2002)
Bioconjug. Chem.
, vol.13
, pp. 729
-
-
Niesner, U.1
Halin, C.2
Lozzi, L.3
Gunthert, M.4
Neri, P.5
Wunderli-Allenspach, H.6
Zardi, L.7
Neri, D.8
-
81
-
-
0035863566
-
Targeted delivery of tissue factor to the ED-B domain of fibronectin, a marker of angiogenesis, mediates the infarction of solid tumors in mice
-
Nilsson F., Kosmehl H., Zardi L., and Neri D. Targeted delivery of tissue factor to the ED-B domain of fibronectin, a marker of angiogenesis, mediates the infarction of solid tumors in mice. Cancer Res. 61 (2001) 711
-
(2001)
Cancer Res.
, vol.61
, pp. 711
-
-
Nilsson, F.1
Kosmehl, H.2
Zardi, L.3
Neri, D.4
-
82
-
-
0022369998
-
Tumor necrosis factor (TNF)
-
Old L.J. Tumor necrosis factor (TNF). Science 230 (1985) 630
-
(1985)
Science
, vol.230
, pp. 630
-
-
Old, L.J.1
-
84
-
-
0037107551
-
Fibronectin at a glance
-
Pankov R., and Yamada K.M. Fibronectin at a glance. J. Cell Sci. 115 (2002) 3861
-
(2002)
J. Cell Sci.
, vol.115
, pp. 3861
-
-
Pankov, R.1
Yamada, K.M.2
-
85
-
-
0035251612
-
Antibody-cytokine fusion proteins for the therapy of cancer
-
Penichet M.L., and Morrison S.L. Antibody-cytokine fusion proteins for the therapy of cancer. J. Immunol. Methods 248 (2001) 91
-
(2001)
J. Immunol. Methods
, vol.248
, pp. 91
-
-
Penichet, M.L.1
Morrison, S.L.2
-
87
-
-
0029038921
-
Dendritic cell loss from nonlymphoid tissues after systemic administration of lipopolysaccharide, tumor necrosis factor, and interleukin 1
-
Roake J.A., Rao A.S., Morris P.J., Larsen C.P., Hankins D.F., and Austyn J.M. Dendritic cell loss from nonlymphoid tissues after systemic administration of lipopolysaccharide, tumor necrosis factor, and interleukin 1. J. Exp. Med. 181 (1995) 2237
-
(1995)
J. Exp. Med.
, vol.181
, pp. 2237
-
-
Roake, J.A.1
Rao, A.S.2
Morris, P.J.3
Larsen, C.P.4
Hankins, D.F.5
Austyn, J.M.6
-
88
-
-
0032748338
-
Interleukin-12 as an adjuvant for cancer immunotherapy
-
Rodolfo M., and Colombo M.P. Interleukin-12 as an adjuvant for cancer immunotherapy. Methods 19 (1999) 114
-
(1999)
Methods
, vol.19
, pp. 114
-
-
Rodolfo, M.1
Colombo, M.P.2
-
89
-
-
0033847583
-
Interleukin-2 and the development of immunotherapy for the treatment of patients with cancer
-
Rosenberg S.A. Interleukin-2 and the development of immunotherapy for the treatment of patients with cancer. Cancer J. Sci. Am. 6 Suppl. 1 (2000) 2
-
(2000)
Cancer J. Sci. Am.
, vol.6
, Issue.SUPPL. 1
, pp. 2
-
-
Rosenberg, S.A.1
-
90
-
-
0029038828
-
An antimelanoma immunotoxin containing recombinant human tumor necrosis factor: tissue disposition, pharmacokinetic, and therapeutic studies in xenograft models
-
Rosenblum M.G., Cheung L., Mujoo K., and Murray J.L. An antimelanoma immunotoxin containing recombinant human tumor necrosis factor: tissue disposition, pharmacokinetic, and therapeutic studies in xenograft models. Cancer Immunol. Immunother. 40 (1995) 322
-
(1995)
Cancer Immunol. Immunother.
, vol.40
, pp. 322
-
-
Rosenblum, M.G.1
Cheung, L.2
Mujoo, K.3
Murray, J.L.4
-
91
-
-
0028060152
-
A recombinant antibody-interleukin 2 fusion protein suppresses growth of hepatic human neuroblastoma metastases in severe combined immunodeficiency mice
-
Sabzevari H., Gillies S.D., Mueller B.M., Pancook J.D., and Reisfeld R.A. A recombinant antibody-interleukin 2 fusion protein suppresses growth of hepatic human neuroblastoma metastases in severe combined immunodeficiency mice. Proc. Natl. Acad Sci. USA 91 (1994) 9626
-
(1994)
Proc. Natl. Acad Sci. USA
, vol.91
, pp. 9626
-
-
Sabzevari, H.1
Gillies, S.D.2
Mueller, B.M.3
Pancook, J.D.4
Reisfeld, R.A.5
-
92
-
-
0037314650
-
Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer
-
Santimaria M., Moscatelli G., Viale G.L., Giovannoni L., Neri G., Viti F., Leprini A., Borsi L., Castellani P., Zardi L., Neri D., and Riva P. Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer. Clin. Cancer Res. 9 (2003) 571
-
(2003)
Clin. Cancer Res.
, vol.9
, pp. 571
-
-
Santimaria, M.1
Moscatelli, G.2
Viale, G.L.3
Giovannoni, L.4
Neri, G.5
Viti, F.6
Leprini, A.7
Borsi, L.8
Castellani, P.9
Zardi, L.10
Neri, D.11
Riva, P.12
-
93
-
-
63849261384
-
Expression of the oncofetal ED-B-containing fibronectin isoform in hematologic tumors enables ED-B-targeted 131I-L19SIP radioimmunotherapy in Hodgkin lymphoma patients
-
Sauer S., Erba P.A., Petrini M., Menrad A., Giovannoni L., Grana C., Hirsch B., Zardi L., Paganelli G., Mariani G., Neri D., Durkop H., and Menssen H.D. Expression of the oncofetal ED-B-containing fibronectin isoform in hematologic tumors enables ED-B-targeted 131I-L19SIP radioimmunotherapy in Hodgkin lymphoma patients. Blood 113 (2009) 2265
-
(2009)
Blood
, vol.113
, pp. 2265
-
-
Sauer, S.1
Erba, P.A.2
Petrini, M.3
Menrad, A.4
Giovannoni, L.5
Grana, C.6
Hirsch, B.7
Zardi, L.8
Paganelli, G.9
Mariani, G.10
Neri, D.11
Durkop, H.12
Menssen, H.D.13
-
94
-
-
0027512894
-
A recombinant single chain antibody interleukin-2 fusion protein
-
Savage P., So A., Spooner R.A., and Epenetos A.A. A recombinant single chain antibody interleukin-2 fusion protein. Br. J. Cancer 67 (1993) 304
-
(1993)
Br. J. Cancer
, vol.67
, pp. 304
-
-
Savage, P.1
So, A.2
Spooner, R.A.3
Epenetos, A.A.4
-
95
-
-
33644834222
-
A human cytokine/single-chain antibody fusion protein for simultaneous delivery of GM-CSF and IL-2 to Ep-CAM overexpressing tumor cells
-
Schanzer J.M., Baeuerle P.A., Dreier T., and Kufer P. A human cytokine/single-chain antibody fusion protein for simultaneous delivery of GM-CSF and IL-2 to Ep-CAM overexpressing tumor cells. Cancer Immun. 6 (2006) 4
-
(2006)
Cancer Immun.
, vol.6
, pp. 4
-
-
Schanzer, J.M.1
Baeuerle, P.A.2
Dreier, T.3
Kufer, P.4
-
96
-
-
0030070734
-
Eastern cooperative group trial of interferon gamma in metastatic melanoma: an innovative study design
-
Schiller J.H., Pugh M., Kirkwood J.M., Karp D., Larson M., and Borden E. Eastern cooperative group trial of interferon gamma in metastatic melanoma: an innovative study design. Clin. Cancer Res. 2 (1996) 29
-
(1996)
Clin. Cancer Res.
, vol.2
, pp. 29
-
-
Schiller, J.H.1
Pugh, M.2
Kirkwood, J.M.3
Karp, D.4
Larson, M.5
Borden, E.6
-
97
-
-
35848962936
-
Antibody-based targeting of the tumor vasculature
-
Schliemann C., and Neri D. Antibody-based targeting of the tumor vasculature. Biochim. Biophys. Acta 1776 (2007) 175
-
(2007)
Biochim. Biophys. Acta
, vol.1776
, pp. 175
-
-
Schliemann, C.1
Neri, D.2
-
98
-
-
63849274108
-
Complete eradication of human B-cell lymphoma xenografts using rituximab in combination with the immunocytokine L19-IL2
-
Schliemann C., Palumbo A., Zuberbuhler K., Villa A., Kaspar M., Trachsel E., Klapper W., Menssen H.D., and Neri D. Complete eradication of human B-cell lymphoma xenografts using rituximab in combination with the immunocytokine L19-IL2. Blood 113 (2009) 2275
-
(2009)
Blood
, vol.113
, pp. 2275
-
-
Schliemann, C.1
Palumbo, A.2
Zuberbuhler, K.3
Villa, A.4
Kaspar, M.5
Trachsel, E.6
Klapper, W.7
Menssen, H.D.8
Neri, D.9
-
100
-
-
0021042241
-
Three different fibronectin mRNAs arise by alternative splicing within the coding region
-
Schwarzbauer J.E., Tamkun J.W., Lemischka I.R., and Hynes R.O. Three different fibronectin mRNAs arise by alternative splicing within the coding region. Cell 35 (1983) 421
-
(1983)
Cell
, vol.35
, pp. 421
-
-
Schwarzbauer, J.E.1
Tamkun, J.W.2
Lemischka, I.R.3
Hynes, R.O.4
-
101
-
-
54949101585
-
Cytokines and their relationship to the symptoms and outcome of cancer
-
Seruga B., Zhang H., Bernstein L.J., and Tannock I.F. Cytokines and their relationship to the symptoms and outcome of cancer. Nat. Rev. Cancer 8 (2008) 887
-
(2008)
Nat. Rev. Cancer
, vol.8
, pp. 887
-
-
Seruga, B.1
Zhang, H.2
Bernstein, L.J.3
Tannock, I.F.4
-
104
-
-
0023226808
-
Immunomodulatory and immunotherapeutic properties of recombinant gamma-interferon and recombinant tumor necrosis factor in mice
-
Talmadge J.E., Tribble H.R., Pennington R.W., Phillips H., and Wiltrout R.H. Immunomodulatory and immunotherapeutic properties of recombinant gamma-interferon and recombinant tumor necrosis factor in mice. Cancer Res. 47 (1987) 2563
-
(1987)
Cancer Res.
, vol.47
, pp. 2563
-
-
Talmadge, J.E.1
Tribble, H.R.2
Pennington, R.W.3
Phillips, H.4
Wiltrout, R.H.5
-
105
-
-
0027394657
-
The IL-2/IL-2 receptor system: a current overview
-
Taniguchi T., and Minami Y. The IL-2/IL-2 receptor system: a current overview. Cell 73 (1993) 5
-
(1993)
Cell
, vol.73
, pp. 5
-
-
Taniguchi, T.1
Minami, Y.2
-
106
-
-
0031110368
-
IL-12 induces T helper 1-directed antitumor response
-
Tsung K., Meko J.B., Peplinski G.R., Tsung Y.L., and Norton J.A. IL-12 induces T helper 1-directed antitumor response. J. Immunol. 158 (1997) 3359
-
(1997)
J. Immunol.
, vol.158
, pp. 3359
-
-
Tsung, K.1
Meko, J.B.2
Peplinski, G.R.3
Tsung, Y.L.4
Norton, J.A.5
-
107
-
-
0024541450
-
Macroscopic and microscopic early effects of tumour necrosis factor on murine Meth A sarcoma, and relation to curative activity
-
Van de Wiel P.A., Bloksma N., Kuper C.F., Hofhuis F.M., and Willers J.M. Macroscopic and microscopic early effects of tumour necrosis factor on murine Meth A sarcoma, and relation to curative activity. J. Pathol. 157 (1989) 65
-
(1989)
J. Pathol.
, vol.157
, pp. 65
-
-
Van de Wiel, P.A.1
Bloksma, N.2
Kuper, C.F.3
Hofhuis, F.M.4
Willers, J.M.5
-
108
-
-
0031873440
-
Biodistribution and tumor localization of stealth liposomal tumor necrosis factor-alpha in soft tissue sarcoma bearing rats
-
van der Veen A.H., Eggermont A.M., Seynhaeve A.L., van T., and ten Hagen T.L. Biodistribution and tumor localization of stealth liposomal tumor necrosis factor-alpha in soft tissue sarcoma bearing rats. Int. J. Cancer 77 (1998) 901
-
(1998)
Int. J. Cancer
, vol.77
, pp. 901
-
-
van der Veen, A.H.1
Eggermont, A.M.2
Seynhaeve, A.L.3
van, T.4
ten Hagen, T.L.5
-
109
-
-
0027392199
-
Human TNF mutants with selective activity on the p55 receptor
-
Van Ostade X., Vandenabeele P., Everaerdt B., Loetscher H., Gentz R., Brockhaus M., Lesslauer W., Tavernier J., Brouckaert P., and Fiers W. Human TNF mutants with selective activity on the p55 receptor. Nature 361 (1993) 266
-
(1993)
Nature
, vol.361
, pp. 266
-
-
Van Ostade, X.1
Vandenabeele, P.2
Everaerdt, B.3
Loetscher, H.4
Gentz, R.5
Brockhaus, M.6
Lesslauer, W.7
Tavernier, J.8
Brouckaert, P.9
Fiers, W.10
-
110
-
-
0033555628
-
Increased binding affinity and valence of recombinant antibody fragments lead to improved targeting of tumoral angiogenesis
-
Viti F., Tarli L., Giovannoni L., Zardi L., and Neri D. Increased binding affinity and valence of recombinant antibody fragments lead to improved targeting of tumoral angiogenesis. Cancer Res. 59 (1999) 347
-
(1999)
Cancer Res.
, vol.59
, pp. 347
-
-
Viti, F.1
Tarli, L.2
Giovannoni, L.3
Zardi, L.4
Neri, D.5
-
111
-
-
20344395758
-
Differential in vivo and in vitro expression of ED-B+ fibronectin in adult human hematopoiesis
-
Vogel W., Berndt A., Muller A., Dahse R., Haas K.M., Borsi L., Zardi L., and Kosmehl H. Differential in vivo and in vitro expression of ED-B+ fibronectin in adult human hematopoiesis. Int. J. Mol. Med. 12 (2003) 831
-
(2003)
Int. J. Mol. Med.
, vol.12
, pp. 831
-
-
Vogel, W.1
Berndt, A.2
Muller, A.3
Dahse, R.4
Haas, K.M.5
Borsi, L.6
Zardi, L.7
Kosmehl, H.8
-
112
-
-
33746547247
-
The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design
-
Waldmann T.A. The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nat. Rev. Immunol. 6 (2006) 595
-
(2006)
Nat. Rev. Immunol.
, vol.6
, pp. 595
-
-
Waldmann, T.A.1
-
113
-
-
0023877120
-
Toxic effect of tumor necrosis factor on tumor vasculature in mice
-
Watanabe N., Niitsu Y., Umeno H., Kuriyama H., Neda H., Yamauchi N., Maeda M., and Urushizaki I. Toxic effect of tumor necrosis factor on tumor vasculature in mice. Cancer Res. 48 (1988) 2179
-
(1988)
Cancer Res.
, vol.48
, pp. 2179
-
-
Watanabe, N.1
Niitsu, Y.2
Umeno, H.3
Kuriyama, H.4
Neda, H.5
Yamauchi, N.6
Maeda, M.7
Urushizaki, I.8
-
115
-
-
0034662638
-
Targeting and therapy of carcinoembryonic antigen-expressing tumors in transgenic mice with an antibody-interleukin 2 fusion protein
-
Xu X., Clarke P., Szalai G., Shively J.E., Williams L.E., Shyr Y., Shi E., and Primus F.J. Targeting and therapy of carcinoembryonic antigen-expressing tumors in transgenic mice with an antibody-interleukin 2 fusion protein. Cancer Res. 60 (2000) 4475
-
(2000)
Cancer Res.
, vol.60
, pp. 4475
-
-
Xu, X.1
Clarke, P.2
Szalai, G.3
Shively, J.E.4
Williams, L.E.5
Shyr, Y.6
Shi, E.7
Primus, F.J.8
-
116
-
-
0028289170
-
Antitumor potential of interferon-gamma: retroviral expression of mouse interferon-gamma cDNA in two kinds of highly metastatic mouse tumor lines reduces their tumorigenicity
-
Yanagihara K., Seyama T., and Watanabe Y. Antitumor potential of interferon-gamma: retroviral expression of mouse interferon-gamma cDNA in two kinds of highly metastatic mouse tumor lines reduces their tumorigenicity. Nat. Immun. 13 (1994) 102
-
(1994)
Nat. Immun.
, vol.13
, pp. 102
-
-
Yanagihara, K.1
Seyama, T.2
Watanabe, Y.3
-
117
-
-
0019363174
-
Monoclonal antibodies: a powerful new tool in biology and medicine
-
Yelton D.E., and Scharff M.D. Monoclonal antibodies: a powerful new tool in biology and medicine. Annu. Rev. Biochem. 50 (1981) 657
-
(1981)
Annu. Rev. Biochem.
, vol.50
, pp. 657
-
-
Yelton, D.E.1
Scharff, M.D.2
-
118
-
-
4143073644
-
Phase II clinical trial of interleukin-12 in patients with relapsed and refractory non-Hodgkin's lymphoma and Hodgkin's disease
-
Younes A., Pro B., Robertson M.J., Flinn I.W., Romaguera J.E., Hagemeister F., Dang N.H., Fiumara P., Loyer E.M., Cabanillas F.F., McLaughlin P.W., Rodriguez M.A., and Samaniego F. Phase II clinical trial of interleukin-12 in patients with relapsed and refractory non-Hodgkin's lymphoma and Hodgkin's disease. Clin. Cancer Res. 10 (2004) 5432
-
(2004)
Clin. Cancer Res.
, vol.10
, pp. 5432
-
-
Younes, A.1
Pro, B.2
Robertson, M.J.3
Flinn, I.W.4
Romaguera, J.E.5
Hagemeister, F.6
Dang, N.H.7
Fiumara, P.8
Loyer, E.M.9
Cabanillas, F.F.10
McLaughlin, P.W.11
Rodriguez, M.A.12
Samaniego, F.13
-
119
-
-
0023392493
-
Transformed human cells produce a new fibronectin isoform by preferential alternative splicing of a previously unobserved exon
-
Zardi L., Carnemolla B., Siri A., Petersen T.E., Paolella G., Sebastio G., and Baralle F.E. Transformed human cells produce a new fibronectin isoform by preferential alternative splicing of a previously unobserved exon. EMBO J. 6 (1987) 2337
-
(1987)
EMBO J.
, vol.6
, pp. 2337
-
-
Zardi, L.1
Carnemolla, B.2
Siri, A.3
Petersen, T.E.4
Paolella, G.5
Sebastio, G.6
Baralle, F.E.7
-
120
-
-
0842343425
-
TNF-alpha coupled to membrane of apoptotic cells favors the cross-priming to melanoma antigens
-
Zimmermann V.S., Bondanza A., Monno A., Rovere-Querini P., Corti A., and Manfredi A.A. TNF-alpha coupled to membrane of apoptotic cells favors the cross-priming to melanoma antigens. J. Immunol. 172 (2004) 2643
-
(2004)
J. Immunol.
, vol.172
, pp. 2643
-
-
Zimmermann, V.S.1
Bondanza, A.2
Monno, A.3
Rovere-Querini, P.4
Corti, A.5
Manfredi, A.A.6
|